In our study we concentrated on the expression of phosphorylated, active EGFR protein as the assessment of active protein (rather than total protein) or gene amplification status seems to be more valuable in terms of patient selection for anti-EGFR cancer therapy and their response to treatment [35], [36]. Here, EGFR is linked to cancer.